Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.
about
Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel diseaseCharacterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveysImpact of medical therapies on inflammatory bowel disease complication rateTreating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseasesCurrent therapy of pediatric Crohn's diseaseCurrent, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.How do patients with inflammatory bowel disease want their biological therapy administered?Biologic Therapies for Crohn's Disease: Update from the 2009 ACG Meeting.Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease.The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data.Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort.Vedolizumab for Crohn's disease.Tailoring the treatment to the individual in Crohn's disease.Utilization trends of anti-TNF agents and health outcomes in adults and children with inflammatory bowel diseases: a single-center experience.Adalimumab safety in global clinical trials of patients with Crohn's disease.The gut microbiome in intestinal fibrosis: environmental protector or provocateur?Current and emerging drugs for the treatment of inflammatory bowel disease.The development and assessment of biological treatments for children.Risk of postoperative recurrence and postoperative management of Crohn's diseaseUpdate on the management of inflammatory bowel disease: specific role of adalimumab.Racial disparities in utilization of specialist care and medications in inflammatory bowel diseaseBiologics in paediatric Crohn's disease.The Value of Vedolizumab as Rescue Therapy in Moderate-Severe Crohn's Disease Patients with Adalimumab Non-response in the USA.Crucial steps in the natural history of inflammatory bowel disease.Costs of Crohn's Disease According to Severity States in France: A Prospective Observational Study and Statistical Modeling over 10 Years.Cost-effectiveness of Crohn's disease post-operative careCrohn's disease complicated by strictures: a systematic review.Clinical prognostic factors for disabling Crohn's disease: a systematic review and meta-analysis.Early surgery in Crohn's disease a benefit in selected cases.Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study.Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis.Infliximab extends the duration until the first surgery in patients with Crohn's disease.Comparative effectiveness of infliximab and adalimumab for Crohn's disease.Prognostic biomarkers to identify patients destined to develop severe Crohn's disease who may benefit from early biological therapy: protocol for a systematic review, meta-analysis and external validation.Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients.Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics.Overview of biologic therapy for Crohn's disease.Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease.High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score.
P2860
Q26827444-D498D01D-2D45-4F1C-990F-1FE44008B481Q26862821-25DAF5F4-DF93-49D9-A541-D6FCFC329C11Q26995479-7879AC9D-BF4C-4B46-A2C3-E427C298528DQ27008246-45A6D85C-8C59-4D77-BD8F-3C8062D7F08EQ28081919-1DBE958C-9CC8-49F5-92CD-55ACE251EF85Q30902172-AEEB4677-D929-4F1D-92A1-4B9CF007963AQ33523157-89984509-1D71-4802-A047-11DAED59F445Q33916292-26789993-8BBD-4B3E-B3CA-ADE26908F4C5Q34127277-3AEA21FE-2A45-4D5D-BBFD-81692C95977BQ34147687-C8BC84BF-E243-4966-B154-FC3AFA42BFC6Q34167771-71F6E6B3-B407-48E7-AD3F-20627B9E31BDQ34175981-7EB13FCB-2892-49D7-9018-B1933DBE9216Q34326912-675F199A-6076-4A46-AB88-1A1026F6B894Q34409001-7C0D5FEE-30CC-41BC-BEEA-06E76609B8C7Q34489872-7D024C1B-A22A-483C-A41D-AAB73F5BBCE3Q34607547-C911A492-10B2-4C98-A803-2090C9682A0BQ34778411-D1070822-5BD0-4087-9F00-1AE63D13B82BQ34883210-63289305-A037-48F4-B1FA-E509AAD34ED5Q35135936-53423C5D-5635-4C31-ABFF-F2D2FA2246CFQ35171537-AA1669F6-5336-4DF2-ABEF-68F4F44E5237Q35186975-D758E501-DB66-48DE-9E53-E8AED284E9F6Q35205595-B813A1E3-B6DD-4CFB-ADAB-B061A88BBFFAQ35579308-25B6EE3B-1FDF-4770-B17C-85D4FF2D19E7Q35634736-97E5913A-0FB2-45D5-B0AD-CCCD6E36A4BFQ36144457-74B6AF9B-EDC7-46D2-95FC-1E35360B1274Q36192570-A76A2B64-C4E6-4D16-B963-94CA30E63A41Q36747868-66EE7624-BC7D-4A8E-BD8E-C293A15AD51EQ36945422-DC0F68D5-D17A-42CF-A280-EBBDD4D65B7AQ36975021-4B225F3E-CDAA-499B-B657-1A71FAF8F39BQ37089435-C867C077-950A-4705-BB4E-D9F851169D0FQ37118400-5FCA8603-A6AE-441E-A853-4CA17D903F6AQ37342575-632F65D3-8DA3-4717-BBD5-BFD26A2F886CQ37382433-12DB5D24-7717-4F49-806E-A2D4DEE130FCQ37445629-7CCEFEAF-1C66-400B-925E-7F3E860521A3Q37460415-39051606-2E6C-4AC5-9D69-5055250CFADDQ37482486-F06728E1-4BE3-428F-8843-6DBC3A040191Q37492480-CD6D87C4-AF61-41E6-9F4C-385D71EC9035Q37547257-09940660-183C-4D80-B9AE-3A54DB7A3DC9Q37571701-37FA66ED-34E6-4FBC-A2BF-943624772826Q37601498-8D01DF30-2820-4794-86FA-986AE140DEDC
P2860
Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Effects of adalimumab therapy ...... results from the CHARM study.
@en
Effects of adalimumab therapy ...... results from the CHARM study.
@nl
type
label
Effects of adalimumab therapy ...... results from the CHARM study.
@en
Effects of adalimumab therapy ...... results from the CHARM study.
@nl
prefLabel
Effects of adalimumab therapy ...... results from the CHARM study.
@en
Effects of adalimumab therapy ...... results from the CHARM study.
@nl
P2093
P50
P1433
P1476
Effects of adalimumab therapy ...... results from the CHARM study.
@en
P2093
Andrew P Yu
Geert R D'Haens
Jingdong Chao
Kathleen G Lomax
Parvez Mulani
Paul J Rutgeerts
Remo Panaccione
Stefan Schreiber
P304
P356
10.1053/J.GASTRO.2008.07.069
P407
P577
2008-08-03T00:00:00Z